| Present-day uses of niacin: effects on lipid and non-lipid parameters. | |
| | |
MedLine Citation:
|
PMID: 17685887 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Existing guidelines for the prevention and treatment of coronary artery disease focus on lowering low-density lipoprotein cholesterol (LDL-C) as the primary lipid target. However, there has been increasing interest in raising high-density lipoprotein cholesterol (HDL-C) due to strong evidence linking low HDL-C levels with an increased risk of atherosclerosis. Raising HDL-C levels with lifestyle changes and pharmacologic interventions appear to reduce the risk of coronary artery disease beyond that of lowering LDL-C alone. Niacin has a substantial HDL-C raising effect, and also may beneficially alter total cholesterol, LDL-C and triglyceride levels. Niacin also exhibits antioxidant, anti-inflammatory and other beneficial effects on atherosclerosis. Niacin is safe and effective to use in women, in patients with diabetes mellitus and/or metabolic syndrome, and when used in combination with statins. Niacin has the promise of being a powerful pharmacologic agent in the fight against atherosclerotic disease, although additional clinical studies are required to examine this further. |
| | |
Authors:
|
Sanjukta Sanyal; Richard H Karas; Jeffrey T Kuvin |
Related Documents
:
|
1448297 - Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cor... 16173527 - Electroacupuncture therapy for weight loss reduces serum total cholesterol, triglycerid... 19186967 - Periodontal status in subjects with hyperlipidemia. 7900717 - Plasma lipid levels and psychologic characteristics in men. 7653657 - Cold-induced alterations in uncoupling protein and its mrna are seasonally dependent in... 11280717 - Nutrient regulation of post-heparin lipoprotein lipase activity in obese subjects. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 8 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-09 Completed Date: 2007-09-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 1711-7 Citation Subset: IM |
Affiliation:
|
Tufts-New England Medical Center, Department of Medicine, Division of Cardiology, Boston, Massachusetts 02111, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cholesterol, HDL / blood* Cholesterol, LDL / blood* Humans Hyperlipidemias / blood, drug therapy Lipids / blood Metabolic Syndrome X / blood, drug therapy Niacin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipids; 59-67-6/Niacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.
Next Document: Clinical pharmacology of celecoxib, a COX-2 selective inhibitor.